Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy

Inclusion Criteria: * Patients who is informed and give a consent in voluntary * Patients who is scheduled a colonoscopy * BMI 19≤ and \<30 Exclusion Criteria: * Patients who participate in other interventional study or had participated within 30 days before screening * Pregnant or breast-feeding women who do not want to stop breast-feeding * Women of childbearing potential who do not agree with appropriate contraception during this study * Patients who had experienced any hypersensitivity study drug or ingredient * Uncontrolled hypertension * Arrhythmia with clinically significant findings from EKG * Congestive heart failure; NYHA functional class III or IV; unstable coronary artery disease; myocardiac infarction history within 6 months * Uncontrolled diabetes * Active infection except acute upper respiratory infection or local skin infection; Fever (38 °C and higher) within 1 week before study administration * HIV infection and/or chronic hepatitis B or C * Patients who has a difficulty to participate because of severe nausea or vomiting * Suspected or confirmed inflammatory bowel disease, toxic colon or toxic megacolon, or gastrointestinal obstruction or perforation; visible bleeding in colon * History of colon surgery and abdominal surgery within 6 month; need an emergency surgery * Colonoscopy for the following use: treatment of bleeding from such lesions as vascular malformation, ulceration, neoplasia, and polypectomy site (e.g.,electrocoagulation, heater probe, laser or injection therapy); foreign body removal; decompression of acute nontoxic megacolon or sigmoid volvulus; balloon dilation of stenotic lesions (e.g., anastomotic strictures); palliative treatment of stenosing or bleeding neoplasms (e.g., laser, electrocoagulation, stenting) * Fluid or electrolyte (Na, K, Ca, Mg, chloride, bicarbonate) disturbance * Severe dehydration risk (e.g., rhabdomyolysis, ascites) * Dialysis or renal disorder (creatinine clearance \<15ml/min) * Suspected pulmonary aspiration or gag reflex disorder * History of hypersensitivity of drug or others * Alcohol or drug abuse within 6 months * Clinically significant underlying disease or medical history at investigator's discretion * Inability in written/verbal communication